Actinium Announces Iomab-B Produces High Response Rates and Significant Improvement in Overall Survival in Relapsed Refractory AML Patients with Active Disease Overcoming TP53 Mutation

/PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today...

Related Keywords

United States ,American ,Hannah Choe ,Astellas Pharma ,Avinash Desai ,American Society Of Hematology Meeting Exposition ,Professor Of Medicine At Ohio State University ,Prnewswire Actinium Pharmaceuticals Inc ,Oncology Lg Chem Life Sciences ,Actimaba National Cancer Institute ,Exchange Commission ,Actinium Pharmaceuticals Inc ,Overall Survival ,Annual American Society ,Hematology Meeting ,Complete Remission ,Assistant Professor ,Ohio State University ,Chief Medical Officer ,Pivotal Phase ,About Actinium Pharmaceuticals ,National Cancer Institute ,Life Sciences ,Actinium Pharmaceuticals ,Nc ,Health Care Amp Hospitals ,Pharmaceuticals ,Medical Pharmaceuticals ,Clinical Trials Amp Medical Discoveries ,Trade Show News ,